Chronic myeloid leukaemia (CML)–dasatinib
On this page
Authority to supply dasatinib through the Pharmaceutical Benefits Scheme (PBS) under the Section 85 Arrangements of the National Health Act 1953.
Dasatinib is available as the sole PBS subsidised therapy for the treatment of patients with chronic myeloid leukaemia (CML), in any disease phase, bearing the Philadelphia chromosome or expressing the transcript BCR-ABL and who have active disease (as defined by current bone marrow pathology) and who have failed an adequate trial of imatinib mesylate.
Restriction details
Either of the following two restrictions must apply before approval will be granted to prescribe dasatinib under the PBS:
- initial treatment for patients of CML who have failed an adequate trial of imatinib mesylate
or - continuing treatment for patients of CML.
The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing dasatinib.
View a full transcript of the dasatinib restriction details
.
Dasatinib will only be PBS subsidised for patients with CML who are not receiving concomitant PBS subsidised imatinib mesylate, nilotinib or interferon alfa therapy.
From 1 November 2008, under the PBS, a patient will be able to trial either dasatinib and/or nilotinib within the intial 18 month treatment period, providing the patient’s CML is not resistant to the first second-line agent.
Dasatinib is not PBS subsidised for patients with CML that is resistant to nilotinib.
Item details
Dose
The maximum dose that can be prescribed is 140 mg per day.
Dasatinib is available in a tablet form presented as one of the following:
- dasatinib 20 mg tablets in a pack size of 60
- dasatinib 50 mg tablets in a pack size of 60
- dasatinib 70 mg tablets in a pack size of 60.
Continuing therapy is dependent on patients demonstrating a response to dasatinib therapy, irrespective of the daily dasatinib dose received.
Repeats
Initial applications: a maximum of two repeats may be requested
Continuing applications: a maximum of five repeats may be requested
Patient eligibility
Patients must meet the relevant criteria as indicated in the restrictions and be eligible to receive pharmaceutical benefits.
Pathology reports
All applicable pathology reports must be provided from an approved Australian pathology authority.
Initial application: A pathology report which confirms that the patient has active disease and supporting pathology to demonstrate failure to an adequate trial of imatinib mesylate must be submitted.
Continuing application: A cytogenetic analysis on bone marrow or quantitive polymerase chain reaction (qPCR) on peripheral blood must be performed:
- between 10 and 18 months of initial treatment with dasatinib, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than one per cent has been demonstrated may receive authorisation for a further 12 months of treatment
- at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than one per cent has been sustained.
Definitions of response:
- a major cytogenic response is defined as less than 35 per cent Philadelphia positive bone marrow cells
- a peripheral blood BCR-ABL level of less than one per cent on the international scale (Blood 108: 28-37, 2006 ) also indicates a response, at least the biological equivalent of a major cytogenetic response.
For bone marrow analyses where standard karyotyping conducted at the time of continuing application is not informative, a copy of a cytogenetic analysis conducted on bone marrow using Fluroescence In Situ Hybridisation (FISH) with BCR-ABL specific probe must be submitted with the application. A copy of the non-informative standard karyotype analysis must be included with the application.
Toxicity and severity descriptors
To ensure that the eligibility of patients can be fully assessed, a comprehensive list of imatinib mesylate toxicity and severity descriptors [PDF, 138Kb]
which should be used in conjunction with the application when demonstrating a Grade 3 or 4 non-haematological toxicity that is imatinib related. The toxicity must be of a severity to necessitate permanent treatment withdrawal.
Lodgement
All initial and continuing application requests must be in writing and sent to:
Medicare Australia
Prior written approval of specialised drugs
Reply Paid 9826
GPO Box 9826
Hobart TAS 7001
(no stamp required if posted in Australia)
Please ensure that all written applications for authorisation include:
- a completed authority prescription form
- a completed dasatinib/nilotinib supporting information form, which for initial applications only includes signed patient and prescriber acknowledgments
- all relevant pathology reports to support current criteria.
For assistance please call 1800 700 270* and select option 3 (8 am to 5 pm EST Monday to Friday).
* Call charges apply from mobile or pay phones only.
Application forms
- Chronic myeloid leukaemia—dasatinib/nilotinib PBS authority application supporting information form—initial treatment—(Form 4190) [PDF, 213Kb]
Lodge this form for a patient starting initial sole PBS subsidised treatment of chronic myeloid leukaemia with dasatinib or nilotinib. The patient and prescriber acknowledgments must also be completed. - Chronic myeloid leukaemia—dasatinib/nilotinib PBS authority application supporting information form—continuing treatment—(Form 4191) [PDF, 196Kb]
Lodge this form for a patient continuing sole PBS subsidised treatment of chronic myeloid leukaemia with either dasatinib or nilotinib.
Important: The information on this website is correct at the time of publishing and is subject to change.
Some documents on this page may require the free Adobe PDF reader.
Last updated: 8 December, 2008